Kyowa Hakko gains Japan rights for Sandoz' rituximab biosimilar

26 January 2016

Mid-size Japanese drugmaker Kyowa Hakko Kirin (TYO: 4151) has entered into an agreement with Sandoz KK, a local subsidiary of Swiss pharma giant Novartis (NOVN: VX), for exclusive marketing rights to Sandoz' biosimilar rituximab in Japan.

Rituximab, the active ingredient of Roche’s (ROG: SIX) blockbuster cancer drug Rituxan/MabThera (rituximab), is a chimeric monoclonal antibody against CD20 for treatment of hematological malignancies. Sandoz is developing a biosimilar rituximab globally which is mainly targeted for the treatment of patients with CD20-positive, indolent B-cell Non-Hodgkin's Lymphoma in Japan.

Terms of the deal

Under the terms of the accord, Kyowa Hakko Kirin will pay Sandoz an up-front fee, subsequent payments for regulatory filing, regulatory approval, and success based milestones as well as royalties. Sandoz will file for marketing authorization of the product. Kyowa Hakko Kirin will be responsible for all sales, marketing and promotion activities in Japan.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK